What is Revolade used for?

Revolade is used to treat a bleeding disorder called (primary) immune thrombocytopenia (ITP) in patients aged 1 year and above who have already taken other medicines (corticosteroids or immunoglobulins), which have not worked. ITP is caused by a low blood platelet count, known as thrombocytopenia. People with ITP have an increased risk of bleeding. Symptoms of patients with ITP include petechiae (pin point sized, flat, round red spots under the skin), bruising, nosebleeds, bleeding gums and not being able to control bleeding if they are cut or injured.

Revolade can also be used to treat low platelet counts in adults with hepatitis C virus (HCV) infections, if they have had problems with side effects while on interferon treatment. Many people with hepatitis C have low platelet counts, not only as a result of the disease, but also due to some of the antiviral medicines that are used to treat it. Taking Revolade may make it easier for you to complete a full course of antiviral medicine (peginterferon and ribavirin).

Revolade may also be used to treat adult patients with low blood counts caused by severe aplastic anaemia (SAA). SAA is a disease in which the bone marrow is damaged, causing a deficiency of the red blood cells (anaemia), white blood cells (leukopenia) and platelets (thrombocytopenia).

How Revolade works

Revolade contains eltrombopag, which belongs to a group of medicines called thrombopoietin receptor agonists. It is used to help increase the number of platelets in your blood. Platelets are blood cells that help to reduce or prevent bleeding. 

More information

For more information about Revolade please consult:

Summary of product characteristics (SmPC) for Revolade

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Patient information leaflet (PIL) for Revolade

This link will take you to the electronic medicines compendium (emc) website, which is a non-Novartis website.

Abbreviations: HCV, hepatitis C virus; ITP, immune thrombocytopenia; SAA, severe aplastic anaemia.

Reference:

  1. Revolade Summary of Product Characteristics.
ONC19-C139(2) September 2020.
×

Ask Speakers

×

Medical Information Request

Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You should also report side effects directly via the Yellow Card Scheme at yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.